Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

8 results

  • Association Between Twin Discordance at 6–9 Weeks' of Gestation and Birthweight Complications
  • Kirsten Palmer, Pavitra Delpachitra, Joseph Onwude, Luk Rombauts, Simon Meagher, Stephen Tong
  • Journal: Twin Research and Human Genetics / Volume 13 / Issue 4 / 01 August 2010
  • Published online by Cambridge University Press: 21 February 2012, pp. 389-392
    • Article
      • You have access
    • PDF
    • Export citation
  • View abstract

    Twins achieved through in-vitro fertilisation often undergo a viability ultrasound at 6–9 weeks of gestation. The presence of inter-twin crown-rump length discordance at this stage is not an uncommon finding; however the clinical significance of this is unknown. We analyzed 218 dichorionic twin pregnancies, producing two live fetuses > 24 weeks gestation, to determine whether inter-twin discordance (≥ 85th centile) in the mid-first trimester was associated with birthweight discordance (> 20%), or small for gestational age (< 10th centile). The incidence of birthweight discordance and small for gestational age infants were determined, with no increased risk found for the discordant population. This may provide some reassurance to treating clinicians.

  • Chapter 19 - The use of growth hormone in IVF
  • from Section 3 - Stimulation
  • Edited by Gab Kovacs, Monash University, Victoria
  • Book: How to Improve your ART Success Rates
  • Published online: 05 July 2011
  • Print publication: 30 June 2011, pp 105-109
  • View extract

    Summary

    The rationale of growth hormone (GH) administration during controlled ovarian stimulation (COH) in in vitro fertilization (IVF) is based on the assumption that increased serum concentrations of GH increases the secretion of insulin-like growth factor 1 (IGF-1) by the ovary, leading to a cascade of intrafollicular events which all converge to promote oocyte development and maturation. Recombinant human GH (hGH) is believed to be safe when it is used in the paediatric management of growth insufficiency and adult growth hormone deficiency. Adult GH-deficient patients treated with hGH experience decreased body fat, increased muscle mass, energy levels, bone density and sexual function, and improved immune system function. More studies of better quality and larger size are required to increase the overall confidence that the addition of hGH to COH really improves the healthy take-home baby rate, the outcome that matters most to IVF patients.